Group 1 - Avalon GloboCare Corp. has entered into definitive agreements for the issuance and sale of 6,372,550 shares of common stock and associated warrants at a purchase price of $0.51 per share [1][3] - The offering is expected to generate approximately $3.25 million in gross proceeds before fees and expenses, with potential additional proceeds of about $6.5 million from the warrants if fully exercised [3] - The Series A-1 warrants will expire five years from stockholder approval, while the Series A-2 warrants will expire eighteen months from stockholder approval [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act and are not registered under the Act or applicable state laws, being available only to accredited investors [4] - The company plans to use the net proceeds for repayment of outstanding debt and for working capital and general corporate purposes [3][4] Group 3 - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1][6] - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is also marketing the KetoAir™ breathalyzer device registered as a Class I medical device [6]

Shares of Avalon GloboCare Corp (NASDAQ:ALBT) are trading sharply higher Thursday morning after Benzinga exclusively reported that the company joined Advanced Micro Devices Inc’s (NASDAQ:AMD) AI Developer Program. Here’s what investors need to know.Avalon Globocare stock is charging ahead with explosive momentum. Why is ALBT stock up today?Avalon Quantum AI Joins AMDIn the release, the Freehold, N.J.-based company said its AI-focused subsidiary, Avalon Quantum AI LLC, has been accepted into the AMD AI Devel ...

Strategic Access to AMD Developer Cloud Expected to Accelerate High-Performance AI Video Generation, and Future Enterprise Automation and Scalable DeploymentFREEHOLD, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that it has been accepted into the Advanced Micro Devices (“AMD”) AI Developer Program, ...

Patent Covers Generation of Multiple Audience-Adaptive Commentary Video Variants While Preserving Factual IntegrityFREEHOLD, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a new U.S. provisional patent application covering an artificial intelligenc ...

Core Insights - The company has successfully converted the majority of its outstanding debentures, significantly strengthening its balance sheet and enhancing shareholder value [1][3][4] Financial Overview - The debentures originated from a June 2024 financing round with an aggregate principal amount of $2.8 million, of which $288 thousand was repaid in cash and $2.6 million was converted into common stock [2] - The conversion eliminates the majority of Avalon's outstanding debt, improving financial transparency and supporting long-term shareholder value creation [2][3] Strategic Implications - The conversion is viewed as a meaningful milestone that strengthens the company's capital structure, enhances capital efficiency, and improves overall financial flexibility [4] - This progress aligns with the company's recent return to compliance with Nasdaq's minimum stockholders' equity requirement, positioning it to execute strategic growth initiatives with greater confidence [4] Company Profile - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in generative AI publishing and software [5] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA, and plans to develop additional diagnostic uses for this technology [5]

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Core Insights - The real estate sector has several oversold stocks that present potential buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Douglas Emmett Inc (NYSE:DEI) has an RSI of 28.5, with a recent stock price of $10.55, down 2.3% on Monday, and a 52-week low of $10.52 [6] - Hudson Pacific Properties Inc (NYSE:HPP) has an RSI of 28.2, with a recent stock price of $9.03, down 3.9% on Monday, and a 52-week low of $9.00 [6] - Avalon Globocare Corp (NASDAQ:ALBT) has an RSI of 27.8, with a recent stock price of $0.81, down 0.9% on Monday, and a 52-week low of $0.78 [6]

Provisional Patent Application Covers Systems and Methods for Evidence-Constrained, Audience-Adaptive Generation of Automated Commentary VideosFREEHOLD, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced that its subsidiary, Avalon Quantum AI LLC, has filed a U.S. provisional patent application covering a ...

Core Viewpoint - Avalon GloboCare Corp's stock is experiencing a decline without any specific news to justify the movement, despite the recent FDA registration renewal for its KetoAir device [1] Group 1: Product Overview - The KetoAir device is a handheld breathalyzer that measures breath acetone concentration (BrAce), a biomarker linked to fat metabolism and nutritional ketosis [2] - Utilizing nano-sensor technology, KetoAir offers real-time, non-invasive insights into metabolic states through breath analysis, targeting individuals on ketogenic diets for various purposes [2] - The device is compatible with both iOS and Android smartphones, with applications available on major app stores [3] Group 2: Market Strategy - Avalon GloboCare plans to launch the KetoAir device in both B2B and B2C markets, enhancing marketing and distribution through its subsidiary, Avalon Quantum AI, LLC [3] - Marketing efforts for the device are set to begin in the second quarter of 2026, which is viewed as a significant milestone for the company [4] Group 3: Stock Performance - The stock is currently trading 31.1% below its 20-day simple moving average (SMA) and 55.5% below its 100-day SMA, indicating strong bearish momentum [5] - Over the past year, shares have decreased by 70.51%, and the stock is closer to its 52-week lows than highs [5] - As of the latest publication, shares were down 23.64% at $0.84, marking a new 52-week low [7]

Core Insights - Avalon GloboCare Corp. has renewed the U.S. FDA establishment registration for the KetoAir™ device, a handheld breathalyzer for ketogenic health management [1][5] - The KetoAir™ device measures breath acetone concentration, providing real-time insights into metabolic state for individuals on ketogenic diets [2][5] - Avalon plans to launch KetoAir™ in both B2B and B2C markets using its Catch-Up™ platform, which is powered by generative AI for marketing and distribution [3][4] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI [5] - The KetoAir™ device is registered as a Class I medical device with the FDA and is intended for weight management, athletic performance, and lifestyle-based ketogenic programs [2][5] - The company is also advancing its intellectual property portfolio through existing patent applications and operates commercial real estate [5]